Topics
Glioblastoma | Treatment | Targeted therapy | LP-184 (Zirdafulven)
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > LP-184 (Zirdafulven)
2026
Schreck KC, Lal B, Zhou J, Lopez-Bertoni H, Holdhoff M, Ewesuedo
R, Bhatia K, Chamberlain M, Laterra J.
Phase
Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety,
Pharmacokinetics, and Translational Optimization of CNS Exposure.
Cancer
Res Commun. 2026 Oct 27;6(10):2519-2528. doi:
10.1158/2767-9764.CRC-26-0518. PMID:
42849034. Trial
registration ID: NCT05933265. ˍ